# A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

> **NCT05583838** · PHASE4 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 157 (actual)

## Conditions studied

- Previously Treated Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** rhTPO
- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT05583838
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-22
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-07-16
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05583838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05583838, "A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05583838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*